Xenon Pharmaceuticals Inc.

Thank you for standing by. My name is Meg, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q2 2024 Sinan Pharmaceuticals, Inc. Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, Press star 1 again. Thank you. I would now like to turn the conference over to Mr. Chad Fugere, VP, IR for Sinan. Please go ahead.

Good afternoon.

Thank you for joining us on our call and webcast to discuss Zenon's second quarter 2024 financial and operating results. Joining me today are Ian Mortimer, Zenon's President and Chief Executive Officer, Dr. Chris Kenney, Zenon's Chief Medical Officer, and Sherry Allens, Zenon's Chief Financial Officer, along with Dr. Chris von Zegern, Zenon's Chief Commercial Officer, who will be available during the Q&A period. Ian will begin with a summary of our recent progress across our business, including a summary of our expanding preclinical pipeline programs. Chris Kenney will provide an overview of our ongoing clinical stage programs, including our plans in major depressive disorder, or MDD. And Sherry will close with a summary of our financial results and anticipated milestones. We will then open the call up for your questions. Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding the timing of and potential results from clinical trials, the potential efficacy, safety profile, future development plans, and current and anticipated indications, addressable markets, regulatory success, and commercial potential of our and our partners' product candidates, the efficacy of our clinical trial design, our ability to successfully develop and achieve milestones, in our clinical development program, the timing and results of our interactions with regulators, our ability to successfully develop and obtain regulatory approvals, anticipated timing of the top-line data readout for our clinical trials of Adesu-Kellner, and our expectation that we will have sufficient cash to fund operations into 2027. Today's press release summarizing Xenon's second quarter 2024 financial results in the accompanying quarterly report on Form 10-Q will be made available under the investor section of our website at xenon-pharma.com and filed with the FCC and on CEDAR+. Now, I would like to turn the call over to Ian.